Amgen (AMGN) Stock Drops Despite Market Gains: Important Facts to Note

Amgen (AMGN) ended the recent trading session at $314.38, demonstrating a -0.53% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 1.77%. Meanwhile, the Dow gained 1.42%, and the Nasdaq, a tech-heavy index, added 2.28%.Shares of the world's largest biotech drugmaker witnessed a gain of 4.3% over the previous month, beating the performance of the Medical sector with its loss of 1.17% and the S&P 500's loss of 5.73%.Investors will be eagerly watching for the performance of Amgen in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be $4.18, reflecting a 5.56% increase from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $8.01 billion, up 7.52% from the year-ago period.Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $20.63 per share and revenue of $35 billion, indicating changes of +3.98% and +4.72%, respectively, compared to the previous year.It's also important for investors to be aware of any recent modifications to analyst estimates for Amgen. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.14% higher. As of now, Amgen holds a Zacks Rank of #3 (Hold).In the context of valuation, Amgen is at present trading with a Forward P/E ratio of 15.32. This expresses a discount compared to the average Forward P/E of 18.52 of its industry.Also, we should mention that AMGN has a PEG ratio of 2.63. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.51 at yesterday's closing price.The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 74, which puts it in the top 30% of all 250+ industries.The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amgen Inc. (AMGN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks